Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial - Takeaways - MDSpire

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • By

  • Chengshui Chen

  • Xinyu Liang

  • Zheng Peng

  • Yan Zou

  • Huijuan He

  • Xiaoyan Zhang

  • Yi He

  • Shixiu Wu

  • May 1, 2026

  • 0 min

Share

  • 1

    Upadacitinib, a selective JAK1 inhibitor, was evaluated for treating severe ICI-related dermatitis in a phase 2 clinical trial.

  • 2

    The trial enrolled 33 patients with grades 3-4 dermatitis, who received 15 mg/d of upadacitinib for 28 days without glucocorticoids.

  • 3

    The study found a 100% resolution rate of dermatitis by day 28, with significant improvement in pruritus within 1 day.

  • 4

    Adverse events were minimal, with no serious AEs reported, suggesting a favorable safety profile for upadacitinib.

  • 5

    The findings indicate that upadacitinib may be a promising alternative to corticosteroids for managing ICI-related dermatitis.

Original Source(s)

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • by Chengshui Chen, Xinyu Liang, Zheng Peng, Yan Zou, Huijuan He, Xiaoyan Zhang, Yi He, Shixiu Wu

  • May 1, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

FOXA2 in cancer: from fundamental biology to clinical translation